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ADOPTIVE INFUSION OF DONOR NK CELLS REDUCES GVHD IN RECIPI-
ENTS OF T-CELL DEPLETED AND T-CELL REPLETE ALLOGENEIC MHC-
MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lundqvist, A., Childs, R. NHLBI, NIH, Bethesda, MD.
Retrospective data suggest that alloreactive NK cell-mediated re-
duction in GVHD and disease relapse may be limited to patients
with AML undergoing T-cell depleted KIR ligand-mismatched al-
logeneic hematopoietic cell transplantation (HCT). Whether NK
cells can mediate similar beneficial effects following MHC-
matched, T-cell replete allogeneic HCT is currently unknown.
We investigated if an infusion of purified donor NK cells would re-
duce GVHD and simultaneously mediate anti-tumor effects in
a murine solid tumor model of MHC-matched allogeneic HCT.
Ten days following intravenous injection of 105 RENCA tumor
cells, BALB/c recipient mice were irradiated (950 cGy) and trans-
planted with 8  106 bone marrow cells from MHC-matched
B10.d2 donors. Recipients of a T-cell replete HCT additionally re-
ceived 15 106 splenocytes fromMHC-matched B10.d2 donors on
day 0 whereas recipients of a T-cell depletedHCT received no sple-
nocytes on day 0 with or without a delayed infusion of donor lym-
phocytes (15  106 splenocytes) on day 14. All mice in groups
receiving splenocytes (day 0 or day 14) developed GVHD (weight
loss, alopecia and hunched posture) by day130 and died before day
160. In contrast, 60% of mice receiving splenocytes and purified
donor NK cells (0.5–5  106) on day 0 or day 14 remained free
of skin GVHD and had significantly lower GVHD scores (see Ta-
ble). Moreover, 40% of transplant recipients receiving splenocytes
and NK cells on either day 0 or day 14 survived $60 days post
transplant. To further characterize the NK cell subset responsible
for prolonging GVHD-free survival, donor NK cells were sorted
into BALB/c non-alloreactive Ly49 ligand-matched (Ly49G2)
and BALB/c alloreactive Ly49 ligand-mismatched (Ly49C) NK
cells. Recipients of Ly49C1 NK cells (given day 15) had signifi-
cantly less GVHD and prolonged survival (p\ 0.01) compared to
HCT recipients receiving Ly49G21 NK cells. No difference inorts of
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.GVHD-free survival was observed between transplant recipients
of Ly49G21NK cells and controls not receiving NK cells. Pulmo-
nary tumor burdenwas significantly (p\0.01) lower in recipients of
Ly49C1 or Ly49G21 NK cells compared to mice not receiving
NK cells. These data provide in vivo evidence that a single infusion
of alloreactive donor NK cells can prolong survival by both reduc-
ing GVHD and mediating anti-tumor effects following MHC-
matched T-cell replete allogeneic HCT.STEM CELL BIOLOGY72
RECIPIENT BASED STRATEGIES FOR IMPROVED TRANSPLANT EFFI-
CIENCY: CD26 INHIBITOR TREATED AND CD26-/- RECIPIENT MICE EX-
HIBIT INCREASED SHORT-TERM HOMING AND LONG-TERM
ENGRAFTMENT OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
Paganessi, L.A., Gregory, S.A., Fung, H.C., Christopherson, K.W. Rush
University Medical Center, Chicago, IL.
Introduction: Through the use of CD26 inhibitors and CD26
deficient mice (CD26-/-), we have previously generated data sug-
gesting that suppression of CD26/DPPIV activity on the transplant
donor cell population could potentially be utilized clinically as
a method of increasing transplant efficiency. However, the clinical
importance of the transplant recipient should not to be overlooked.
We therefore investigated whether inhibition or loss of CD26 activ-
ity in the recipient would have an effect on hematopoietic stem cell
transplantation utilizing an in vivo congenic mouse model of trans-
plantation. Methods: The short-term homing and long-term en-
graftment of BoyJ donor cells (expressing CD45.11) into lethally
irradiated control C57BL/6, CD26 inhibitor (Diprotin A) treated
C57BL/6, or CD26-/- mice (expressing CD45.21) was monitored
by flow cytometric analysis of the bone marrow and peripheral
blood at 24 hours and 6 months post-transplant. Results:
Twenty-four hours post-transplant of 20  106 BoyJ mononuclear
cells, we observed 8.85 6 0.58%, 10.69 6 1.01%, and 12.45 6
1.33% donor derived Sca-11lin- cells in the bone marrow of recip-
ient mice for control, Diprotin A treated, and CD26-/- recipient
mice respectively. As compared to control mice, this represents
a 20.8% increase (p 5 0.01) with CD26 inhibitor treatment and
a 40.7% increase (p# 0.05) resulting from the use of a CD26-/- re-
cipient in short-term homing (N 5 5 mice per group). Six months
post-transplant of 1  105 BoyJ mononuclear cells, we observed
39.906 4.38%, 70.226 3.72%, and 92.51 6 1.04% donor contri-
bution to hematopoiesis in the peripheral blood of control, Dipro-
tin A treated, and CD26-/- recipient mice respectively. This
represents a 76.0% increase (p # 0.01) with CD26 inhibitor treat-
ment and a 131.9% increase (p# 0.01) as a result of the CD26-/- re-
cipient in long-term engraftment as compared to control recipient
mice (N5 14 mice per group).Conclusions:These results provide
pre-clinical evidence of the importance of CD26 expression within
the transplant recipient with regard to regulating hematopoietic
stem cell homing and engraftment. Our results also support the po-
tential use of CD26 inhibitors to treat transplant patients during he-
matopoietic stem cell transplantation as a method of improving
transplant efficiency.
73
HUMAN HEMATOPOIETIC PROGENITORS WITH SLOW DIVISIONAL KI-
NETICS RECONSTITUTE T CELLS IN THYMUS, B CELLS IN LYMPH NODES
AND MYELOID CELLS IN MARROW OF NOD/SCID MOUSE MODEL AND
REPRESENT THE MOST PRIMITIVE FRACTION
Schubert, M.1, Zoeller, M.2, Ho, A.D.1. 1University of Heidelberg, Hei-
delberg, Germany; 2German Cancer Research Center, Heidelberg, Ger-
many.
We have demonstrated that CD341 cells with slow division ki-
netics are associated with self renewal and increased frequency of
LTC-IC and myeloid-lymphoid initiating cells (ML-IC) in vitro.
The present study showed that only the slow dividing fraction
(SDF) of human CD341 cells, but not the fast dividing fraction
(FDF), is able to engraft the thymus and lymph nodes of NOD/
SCID mice.
